BIOLOGICAL TREATMENTS AND CARDIOVASCULAR CHANGES IN THE GEORGIAN PATIENT WITH RHEUMATOID ARTHRITIS.

Q4 Medicine
Georgian medical news Pub Date : 2024-11-01
N Tavberidze, N Sharashidze, T Bochorishvili
{"title":"BIOLOGICAL TREATMENTS AND CARDIOVASCULAR CHANGES IN THE GEORGIAN PATIENT WITH RHEUMATOID ARTHRITIS.","authors":"N Tavberidze, N Sharashidze, T Bochorishvili","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Aim: </strong>The aim of the study is to determine the effect of anti-inflammatory biological drugs (adalimumab, infliximab and rituximab) on the cardiovascular system during the treatment of patients with rheumatoid arthritis.</p><p><strong>Methods: </strong>Involved in research 70 women aged 18 to 60 years with a confirmed diagnosis of rheumatoid arthritis (diagnosis confirmed by the American College of Rheumatology 2010 (ACR) and European League of Rheumatology (EULAR) classification criteria). Patients on standard treatment and biological drugs were divided into 3 groups, and the third group was divided into two subgroups. The study lasted for 30 weeks. Studies were conducted before and after treatment.</p><p><strong>Results: </strong>After 30 weeks of treatment with biological drugs, the following changes were observed in all groups: DAS28-ESR and HAQ score values, RF, CRP, and ESR concentrations were significantly lower compared to the control group. A significant increase in TC and HDL-C, without significant changes in LDL-C and TG, was observed in all groups against the background of treatment with biological drugs, as a result of which the atherogenicity index decreased. Decreases in CRP levels at 30 weeks were inversely correlated with increases in HDL-cholesterol. Insignificant changes were observed in fasting blood glucose SBP, DBP and BMI data compared to the control group. Combined therapy with biological drugs led to a significant improvement in the elastic properties of arterial walls.</p><p><strong>Conclusion: </strong>Before starting the treatment of biological drugs in patients with rheumatoid arthritis, the risk of cardiovascular evaluation is full and according to this we need to choose biological drugs and this way we can increase the side effects of drugs.</p>","PeriodicalId":12610,"journal":{"name":"Georgian medical news","volume":" 356","pages":"13-17"},"PeriodicalIF":0.0000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Georgian medical news","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Aim: The aim of the study is to determine the effect of anti-inflammatory biological drugs (adalimumab, infliximab and rituximab) on the cardiovascular system during the treatment of patients with rheumatoid arthritis.

Methods: Involved in research 70 women aged 18 to 60 years with a confirmed diagnosis of rheumatoid arthritis (diagnosis confirmed by the American College of Rheumatology 2010 (ACR) and European League of Rheumatology (EULAR) classification criteria). Patients on standard treatment and biological drugs were divided into 3 groups, and the third group was divided into two subgroups. The study lasted for 30 weeks. Studies were conducted before and after treatment.

Results: After 30 weeks of treatment with biological drugs, the following changes were observed in all groups: DAS28-ESR and HAQ score values, RF, CRP, and ESR concentrations were significantly lower compared to the control group. A significant increase in TC and HDL-C, without significant changes in LDL-C and TG, was observed in all groups against the background of treatment with biological drugs, as a result of which the atherogenicity index decreased. Decreases in CRP levels at 30 weeks were inversely correlated with increases in HDL-cholesterol. Insignificant changes were observed in fasting blood glucose SBP, DBP and BMI data compared to the control group. Combined therapy with biological drugs led to a significant improvement in the elastic properties of arterial walls.

Conclusion: Before starting the treatment of biological drugs in patients with rheumatoid arthritis, the risk of cardiovascular evaluation is full and according to this we need to choose biological drugs and this way we can increase the side effects of drugs.

格鲁吉亚类风湿关节炎患者的生物治疗和心血管变化。
目的:本研究旨在确定抗炎生物药物(阿达木单抗、英夫利昔单抗和利妥昔单抗)在类风湿关节炎患者治疗过程中对心血管系统的影响。方法:纳入研究70例确诊为类风湿性关节炎的女性,年龄18 ~ 60岁(诊断经2010年美国风湿病学会(ACR)和欧洲风湿病学会(EULAR)分类标准确认)。采用标准治疗和生物药物治疗的患者分为3组,第三组分为2个亚组。研究持续了30周。研究在治疗前后进行。结果:生物药物治疗30周后,各组患者DAS28-ESR、HAQ评分值、RF、CRP、ESR浓度均显著低于对照组。在生物药物治疗的背景下,所有组的TC和HDL-C均显著升高,LDL-C和TG无明显变化,导致动脉粥样硬化指数下降。30周时CRP水平的降低与高密度脂蛋白胆固醇的升高呈负相关。与对照组相比,空腹血糖、收缩压、舒张压和BMI数据变化不显著。生物药物联合治疗可显著改善动脉壁的弹性特性。结论:类风湿关节炎患者在开始生物药物治疗前,心血管风险评估是充分的,根据此需要选择生物药物,这样可以增加药物的副作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Georgian medical news
Georgian medical news Medicine-Medicine (all)
CiteScore
0.60
自引率
0.00%
发文量
207
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信